← Back to Search

Attention Modification Program for Obsessive-Compulsive Disorder (AMPOCD Trial)

Phase 1
Waitlist Available
Led By John Piacentini, PhD
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-treatment (week 0) and post-treatment (week 5)
Awards & highlights

Summary

Pediatric Obsessive Compulsive Disorder (OCD) is a chronic, impairing condition that accrues significant concurrent and long-term risk to affected youth. Although empirically supported psychosocial and pharmacological treatments for OCD exist, many children and their families are not able to adequately access these treatments or derive only partial benefit from them. Such findings highlight the importance of developing more effective treatment options which have the potential to be widely accessible to OCD youth. The investigators are proposing to test a computerized attention modification program, AMP, in six youth with OCD in an open case series to gather information regarding protocol acceptability, feasibility and preliminary efficacy. This phase includes the development and refinement of stimuli selection procedures, behavior avoidance task, EEG protocol, and AMP parameters for use with children. Following ascertainment of study eligibility, participants will undergo a baseline assessment consisting of a clinical interview, neurocognitive assessments, EEG, attention bias assessment, and self report questionnaires. Study participants will then receive 12 sessions of AMP treatment over the course of three weeks. All youngsters and their families will be reassessed at treatment endpoint (week 4). Participation will take a total of about 24 hours over the course of six weeks. Participants who are treatment responders may be asked to return approximately 3 months after completing treatment for a follow-up assessment. Preliminary hypotheses: 1) AMP will be acceptable to youth and families and feasible to administer; 2) Youth receiving AMP will demonstrate decreases in threat bias and OCD symptom severity.

Eligible Conditions
  • Obsessive-Compulsive Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-treatment (week 0) and post-treatment (week 5)
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-treatment (week 0) and post-treatment (week 5) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Attention Bias Assessment Change from Pre-Treatment to Post-Treatment

Trial Design

1Treatment groups
Experimental Treatment
Group I: Attention Modification ProgramExperimental Treatment1 Intervention
Attention Modification Program
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Attention Modification Program
2017
Completed Phase 1
~130

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,881 Previous Clinical Trials
2,798,868 Total Patients Enrolled
65 Trials studying Obsessive-Compulsive Disorder
13,916 Patients Enrolled for Obsessive-Compulsive Disorder
University of California, Los AngelesLead Sponsor
1,557 Previous Clinical Trials
10,263,870 Total Patients Enrolled
10 Trials studying Obsessive-Compulsive Disorder
635 Patients Enrolled for Obsessive-Compulsive Disorder
John Piacentini, PhDPrincipal InvestigatorUniversity of California, Los Angeles
2 Previous Clinical Trials
167 Total Patients Enrolled
1 Trials studying Obsessive-Compulsive Disorder
47 Patients Enrolled for Obsessive-Compulsive Disorder
~0 spots leftby Oct 2025